

Drugmaker Sanofi's decision to abandon its 2025 profit target has led to a 15.5% drop in its stock value, wiping off $21 billion. The company plans to focus on long-term profitability and increase spending on immunology and inflammation drug development. Sanofi is considering potential separation scenarios, including creating a listed entity in France. The stock is currently undervalued compared to peers. CEO Paul Hudson expresses confidence in the core innovative drugs business.


Drugmaker Sanofi's decision to abandon its 2025 profit target has led to a 15.5% drop in its stock value, wiping off $21 billion. The company plans to focus on long-term profitability and increase spending on immunology and inflammation drug development. Sanofi is considering potential separation scenarios, including creating a listed entity in France. The stock is currently undervalued compared to peers. CEO Paul Hudson expresses confidence in the core innovative drugs business.
•The company plans to focus on long-term profitability and increase spending on immunology and inflammation drug development.
•Sanofi is considering potential separation scenarios, including creating a listed entity in France.
•The stock is currently undervalued compared to peers.
•CEO Paul Hudson expresses confidence in the core innovative drugs business.







